Apr. 22 at 2:34 PM
$PPCB We are advancing PRP, our lead oncology program, toward its first clinical study, with a clear focus on execution across research, manufacturing, and regulatory preparation. As we move into this next phase, visibility becomes an important part of how we communicate progress.
Throughout the year, we expect to participate in conferences and industry events that create opportunities to engage more directly with the investor community and peers across the sector. These moments matter because they provide space for deeper discussion around our strategy, scientific approach, and development pathway.
As we continue building toward clinical milestones, maintaining an open and consistent dialogue remains a priority. The focus stays on execution while increasing transparency along the way.
